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Metabolism of meta-bromobenzoic acid by the blocked mutant Ralstonia eutrophus B9 affords an 
enantiopure dearomatised halodiene-diol which we demonstrate is a versatile chiron for organic 
synthesis. The presence of the halogen leads to reactivity that is distinct to that observed for the 10 
non-halogenated analogue and also serves as a synthetic handle for further functionalization. 
Introduction 
The dearomatising dihydroxylation of an aromatic substrate 
by a microorganism was first reported by Gibson over 40 
years ago.1 It was subsequently recognised that the resultant 15 
diene diols were useful starting materials for synthesis owing 
to their densely-packed, differentiated functionality. Indeed, 
their synthetic value is enhanced further by the fact that 
substituted arenes give rise to enantiopure diols in most 
instances. The production and utilisation of these arene-20 
derived diols has become established methodology and the 
field has been the subject of several excellent reviews.2 
 Thus far, over 400 arene cis-diol products have been 
reported. The vast majority of these are produced by 
organisms expressing toluene dioxygenase (TDO), 25 
naphthalene dioxygenase (NDO) and biphenyl dioxygenase 
(BPDO) enzymes. These metabolise substituted arene 
substrates in a regio- and stereoselective fashion. A reliable 
predictive model has been reported for such transformations3 
and the sense of enantioinduction is conserved across 30 
organisms and substrates (Scheme 1a, ortho-meta 
oxygenation). In contrast, organisms expressing benzoate 
dioxygenase (BZDO) enzymes oxidise benzoic acids in a 
process that exhibits not only different regioselectivity, but 
also the opposite sense of enantioinduction. For example, R. 35 
eutrophus B9,4 P. putida U1035 and P. putida KTSY01 
(pSYM01)6 oxidise benzoic acid to benzoate 1,2-cis 
dihydrodiol 4 (Scheme 1b, ipso-ortho oxygenation). 
 
Scheme 1 Regio- and stereoselectivity of dioxygenases. 40 
Diol acid 4 has seen several diverse applications in organic 
synthesis to date. In 1995, Widdowson et al. reported the 
production of 4 with P. putida U103.7 The absolute 
stereochemistry of 4 was determined by means of X-ray 
crystallographic analysis of a para-bromobenzoyl derivative. 45 
The ability of derivatives of 4 to participate in [4+2] 
cycloadditions with various dienophiles was also 
demonstrated. In 2001, Myers et al. described multiple 
approaches for elaborating 4, demonstrating that each position 
on the ring could be functionalised in a selective fashion 50 
through judicious choice of reaction sequence.8 They also 
described in detail a large-scale preparation of 4. That the 
derivatives described therein are of synthetic utility was first 
shown by the report in 2004 of the synthesis of carbocyclic 
analogues of topiramate.9 In this work, Parker et al. described 55 
a route to analogues of this anticonvulsant agent, requiring 
between 3 and 4 steps from one of Myers’ chirons; the authors 
also describe the first use of 4 to access a carbohydrate target, 
carba-β-L-fructopyranose. Also in 2004, Mihovilovic et al. 
reported intramolecular Diels–Alder reactions of derivatives 60 
of 4 bearing tethered dienophiles.10 In 2005, Myers et al. 
disclosed the total synthesis of natural and unnatural 
tetracycline antibiotics11 via a synthetic sequence 
commencing from a derivative of 4 they had described four 
years previously.8 It is noteworthy that whilst the first 65 
stereocentre in the target tetracyclines was set in the arene 
dihydroxylation step, all subsequent stereocentres were 
installed under substrate control; all stereochemical 
information in the final products is thus of ultimate enzymatic 
origin. In 2010, the Mihovilovic group published a full 70 
paper12 on intramolecular Diels–Alder reactions with 4 and, 
most recently, the chemistry of 4 has been augmented by our 
report that simple derivatives of 4 are amenable to 
complexation to form tricarbonyliron(0)diene complexes.13 
We have been able to demonstrate that such complexation 75 
permits the synthesis of otherwise inaccessible moieties. Most 
notably a diene possessing the ortho,meta pattern of 
oxygenation found in 2 but antipodal to 2 may be accessed 
from 4 by means of such organoiron complexes.14 
 The unique synthetic versatility of 4 has thus been 80 
demonstrated. However, we sought to enhance further the 
utility of the BZDO-mediated benzoate dihydroxylation by 
use of substituted benzoate substrates. The viability of 
metabolising substituted benzoates by this approach has been 
established previously. Studies on Ralstonia eutrophus B9† 85 
have shown that a variety of mono- and disubstituted 
benzoates are acceptable substrates. It was noted that turnover 
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rates decreased in accordance with the steric demand of a 
substituent, with the ortho position being least tolerant of 
substitution (only ortho-fluorobenzoate underwent 
dioxygenation) and the meta position being the most 
tolerant.4,15 Many other organisms expressing BZDOs have 5 
been evaluated for their ability to process substituted 
benzoates,16 as have organisms expressing TADO17 (toluate 
dioxygenase), TERDOS18 (terephthalate dioxygenase), 
IPADO19 (isophthalate dioxygenase). To our knowledge, 
however, there is just one example to date of the use in 10 
synthesis of an arene dihydrodiol derived from a substituted 
benzoate: Banwell’s use of a metabolite derived from meta-
ethyltoluene in an approach to vinblastine20 (Scheme 2). 
 
Scheme 2 Banwell’s access to arene diol 7 via meta-ethylbenzoic acid. 15 
In the present study, we opted to exploit arene diols derived 
from the metabolism of meta-bromobenzoic acid by R. 
eutrophus B9 (Scheme 3). We anticipated a twofold effect due 
to incorporation of a bromine in the products. Firstly, this 
halide would modulate the electron density of the diene such 20 
that it would exhibit reactivities distinct from those of the 
parent system 4. Secondly, a bromodiene would be amenable 
to diverse cross-coupling reactions to permit further 
functionalization in a manner that would not be possible for 
unsubstituted diene 4. 25 
 
Scheme 3 Arene diol metabolites of meta-bromobenzoic acid. 
As is the case for any meta-substituted benzoate, metabolism 
of 8 may give rise to two regioisomeric diols, 9 and 10, 
reflecting the possibility of the substrate being accommodated 30 
in two possible orientations in the BZDO active site. In the 
specific case of substrate 8, literature precedent was 
ambiguous. In their original report on R. eutrophus B9,4 
Reiner and Hegeman describe the isolation of both 3- and 5-
substituted arene diols from the metabolism of meta-35 
substituted benzoates, but product ratios were not quantified. 
Subsequently, Knackmuss and Reineke quantified product 
formation and found that 5-substituted diols analogous to 10 
were formed more rapidly than the corresponding 3-
substituted regioisomers analogous to 9.15a In both of the 40 
above studies, however, only meta-chloro- and meta-methyl 
benzoate were employed as substrates, not meta-
bromobenzoate 8. Reineke and co-workers’ subsequent 
study15c has been the only one thus far to specifically address 
the metabolism of meta-bromobenzoate 8 by R. eutrophus B9. 45 
Whilst the production of both 9 and 10 is described, the 
product ratio was not determined. In this same study, it is 
stated that when using meta-methylbenzoate, the 5-methyl 
analogue of 10 is “accessible only with difficulty”, whereas 
the 3-methyl analogue of 9 is “isolable in good yield”; such 50 
statements seem to contradict the earlier study.15a Thus, it was 
unclear at the outset what the regiochemical outcome of 
metabolism of 8 by R. eutrophus B9 would be. 
Results and Discussion 
We undertook the biooxidation of 8 in accordance with the 55 
procedure of Myers et al.,8 but on a 15 L scale. R. eutrophus 
B9 cells were induced with a small quantity of benzoate 
before addition of sodium meta-bromobenzoate solution 
portionwise over 48 h; disodium succinate solution was added 
as sole carbon source. The fermentation broth was then 60 
centrifuged to remove cellular material and the supernatant 
was concentrated under reduced pressure. The concentrate 
was acidified to pH 3.0 and extracted numerous times with 
ethyl acetate. Organic washings were dried, then concentrated 
under reduced pressure to give a crude mixture of 8, 9 and 10. 65 
NMR analysis indicated that unreacted 8 was the major 
constituent of the crude mixture. meta-Bromobenzoate 8 had 
been introduced to the fermentation vessel at a rate 
comparable to that used previously8 in the non-halogenated 
case, but R. eutrophus B9 metabolised the brominated 70 
substrate much more slowly, as expected, leading to 
accumulation of unreacted 8. Formation of 3-bromo product 9 
was found to have predominated (>10:1) over the 5-bromo 
isomer 10. 
 Purification of this crude material was effected by repeated 75 
trituration with dichloromethane; this served to remove both 
the starting material 8 and also the traces of 5-bromo product 
10. After 7 triturations, NMR analysis showed the residual 
quantity of 8 to be negligible. By this means, pure 3-bromo 
product 9 was obtained in a yield of 65 mg per litre of 80 
fermentation broth, approximately two orders of magnitude 
lower than those reported for the unsubstituted benzoate.8 
 With access to 9 secured we sought to verify the absolute 
stereochemistry through X-ray analysis of a crystalline 
derivative. The configuration of 4 was originally determined 85 
by Widdowson et al. through formation of the corresponding 
para-bromobenzoylmethyl ester and subsequent X-ray 
analysis;7 the same approach was adopted to determine the 
configuration of 7.20 However, as 9 already incorporates a 
heavy atom, we opted instead to target a crystalline 90 
cycloadduct. Esterification of 9 by means of (trimethylsilyl) 
diazomethane to give 11 was followed by diol protection as 
acetonide 12. Upon treatment with 4-phenyl-1,2,4-triazoline-
3,5-dione, 12 underwent [4+2] cycloaddition to afford 
crystalline adduct 13 (Scheme 4).21 95 
 
Scheme 4 Formation of crystalline derivative. 
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Single crystals of 13 suitable for X-ray structure 
determination were obtained from diffusion of petroleum 
ether into a solution of 13 in ethyl acetate. The structure of 13 
is depicted in Figure 1 and confirms the absolute 
stereochemistry as (1S,2S). Thus, the sense of 5 
enantioinduction in the formation of 9 is the same as in the 
formation of 4 and 7, as expected. 
 
Fig. 1 Solid state structure of 13. Ellipsoids are represented at 50% 
probability. H atoms are shown as spheres of arbitrary radius. 10 
That the sole cycloadduct formed (13) is that in which the 
dienophile approaches anti to the acetonide is in keeping with 
Widdowson’s precedent.7 Aside from that report, all literature 
examples of heterodienophile cycloadditions with arene diol 
derived acetonides involve substrates with the ortho-meta 15 
pattern of oxygenation (c.f. 2). Here also, every report 
describes dienophile addition anti to the acetonide.22,23 In 
such substrates the original arene substituent is attached to the 
diene. In contrast, in 12 (which has the ipso-ortho pattern of 
oxygenation, c.f. 4), the original arene substituent is attached 20 
to an sp3 centre and will not be coplanar with the diene. If the 
substituent is of sufficient steric bulk, approach of the 
dienophile to both diene faces may be hindered. Exclusive 
formation of 13 in this instance is indicative of the steric bulk 
of the acetonide being the controlling factor in determining 25 
regioselectivity of cycloaddition, not steric bulk of the ester. 
 The above considerations are also relevant in the context of 
Diels–Alder dimerisation. Arene diol derived acetonides with 
the ortho-meta pattern of oxygenation (c.f. 2) are known to 
undergo spontaneous dimerization in many instances; this has 30 
been reported with halodienes, e.g. R = Br,23j,24a-c Cl23j,24b,c 
and also with many other substituents on the diene (R = 
CF3,
23b,j,24c R = C2H3,
23j,24c,d R = CN,24e R = COOMe,24f R = 
COOEt,23w R = COOCH2CCH,
23w R = SiMe2H,
24g,h R = 
SiMe2C2H3
24g,h and R = Me24i). In each instance, the 35 
dimerisation is reportedly totally selective for formation of the 
adduct which is anti both with respect to the diene and also 
the dienophile. (The only reported exception to this trend is 
dimerisation of the acetonide of the parent unsubstituted diene 
2, R = H25 – a minor cycloadduct deriving from syn diene 40 
addition and anti dienophile addition has also been 
reported22,26). The behaviour of the bromodiene acetonide 12 
reported here is in marked contrast to the above cases, in that 
we have observed no dimerisation of 12 upon prolonged 
storage at room temperature or below. Dimerisation of the 45 
non-brominated analogue of 12 has also not been reported. 
We ascribe this inertness to dimerisation to the fact that such 
acetonides with the ipso-ortho pattern of oxygenation (c.f. 4) 
present sterically demanding substituents on both sides of the 
diene, hence retarding the formation of all possible isomeric 50 
dimers. 
 We next examined the susceptibility of the bromodiene to 
oxidative elaboration. Neither 11 nor 12 gave tractable 
products upon attempted epoxidation with mCPBA, in 
contrast to the corresponding non-halogenated dienes.8 55 
However, osmium tetroxide-mediated dihydroxylation of 12 
proceeded smoothly to afford diol 14 as the sole regio- and 
diastereoisomer (Scheme 5). Such selectivity is also in 
contrast to the non-halogenated series, wherein the 
corresponding diene 15 undergoes dihydroxylation to afford a 60 
5:1 mixture of regioisomers favouring the other olefin.8 The 
installation of the free diol functionality in 14 on the β-face 
was confirmed by NOESY NMR experiments.‡ Reductive 
elaboration of bromodiene 12 also proceeded in a markedly 
different fashion to the non-halogenated analogue 15. 65 
Whereas LiAlH4-mediated reduction of the ester in 15 to give 
16 is reportedly7,10,12 high-yielding (Scheme 6a), the 
corresponding reduction of bromodiene 12 affords the primary 
alcohol 17 in only 11% yield. We ascribe this low yield partly 
to the concomitant formation of appreciable amounts of 70 
debrominated product 16, which we have isolated (Scheme 
6b). 
 
Scheme 5 Dihydroxylation on the β-face. Selected NOESY correlations 
in 14 shown with double-headed arrows. 75 
 
Scheme 6 Reductive transformations. 
The complexation of arene diols of type 2 with a 
tricarbonyliron fragment has been extensively studied.27 We 
have reported previously13 on complexation of 18 (the methyl 80 
ester of 4) to afford 19 as the sole product, with iron 
complexed to the α-face (Scheme 7a). A later attempt14 to 
reverse the facial selectivity in this complexation by use of an 
acetonide 15 to block the α-face did indeed result in 
complexation of iron to the diene β-face, but the isolated 85 
product (20) was that in which acetonide migration had 
occurred (Scheme 7b). We were therefore keen to determine 
the outcome of complexation of bromodiene acetonide 12 as 
an iron carbonyl in order to shed light on the mechanism of 
formation of 20. In the event, treatment of 12 with 90 
nonacarbonyldiiron in THF afforded isomeric complexes 21 
and 22, in which 21 was the major isomer (Scheme 7c). The 
 4  |  Journal Name, [year], [vol], 00–00 This journal is © The Royal Society of Chemistry [year] 
structure of 21 was determined unambiguously by X-ray 
crystallography (Figure 2). (The minor isomer 22, which was 
appreciably less stable than 21, could not be crystallised 
successfully; its structure was assigned by 2D NMR 
experiments‡ and by comparison with 21.) In this instance, the 5 
sole products are those in which acetonide migration has not 
occurred. This may be explained by the fact that in 12, the 
carbon to which an acetonide oxygen would be bonded upon 
rearrangement already bears the bromine substituent. We had 
previously concluded that the formation of 20 arose via 10 
“clockwise” migration of the acetonide, rather than 
“anticlockwise” migration of the ester.14 The absence of any 
such rearrangement in the case of bromodiene 12 is in keeping 
with this conclusion. The presence of the bromine in 12 also 
retards the rate of complexation with respect to unsubstituted 15 
analogue 15 – identical reaction conditions result in 
consumption of all of 15, but recovery of 60% unreacted 12 
(Scheme 7). 
 20 
Scheme 7 Iron complex formation for various related dienes. 
 
Fig. 2 Solid state structure of 21. Of two independent molecules in the 
unit cell, only one is shown for clarity. Ellipsoids are represented at 50% 
probability. H atoms are shown as spheres of arbitrary radius. 25 
The above transformations of bromodiene 12 represent cases 
in which the presence of the halogen modulates the reactivity 
of the system with respect to the unsubstituted diene case. 
However, we wished to exploit further the value inherent in 
the bromine substituent by using transformations that would 30 
not be possible for the unsubstituted case. A dienyl bromide is 
suggestive of applications in cross-coupling chemistry and in 
the more common ortho,meta arene dihydrodiol series, both 2 
(R = Br)24a,28 and 2 (R = I)28a,h,n,29 have indeed been exploited 
in this context. To date, such cross-couplings have not been 35 
reported for derivatives of 4. 
 We first examined a Suzuki-Miyaura coupling30 of 
protected bromodiene 12 with para-tolylboronic acid. Union 
of these fragments under palladium catalysis was indeed 
achieved, although it was found that the reaction conditions 40 
also effected ester hydrolysis. The free acid 23, recovered 
from the aqueous phase, was re-subjected to esterification 
with (trimethylsilyl)diazomethane to afford the originally 
targeted methyl ester 24, albeit in moderate yield (Scheme 8). 
A much more straightforward cross-coupling was the 45 
Sonogashira31 reaction of 12 with (triisopropylsilyl)acetylene, 
which afforded the dienyne 25 in near-quantitative yield 
(Scheme 8). 
 
Scheme 8 Cross-couplings of the bromodiene. 50 
Dienyne 25 is a useful intermediate for further 
functionalization. Desilylation with TBAF affords terminal 
acetylene 26, which is amenable to the Huisgen32 copper-
catalysed azide-alkyne cycloaddition protocol. We have 
demonstrated this through the reaction of 26 with benzyl azide 55 
to afford triazole 27 (Scheme 9). 
 
Scheme 9 Azide-alkyne “click” cycloaddition. 
Conclusions 
We have demonstrated the versatility of a halobenzoate-60 
derived ipso,ortho-oxygenated arene dihydrodiol in various 
synthetic contexts and shown that the presence of the halogen 
fundamentally alters the course of the reaction in many 
instances. The formation of cross-coupling products 23-27 is 
especially significant, as these structures are arene 65 
dihydrodiol derivatives that would not be accessible by direct 
metabolism of the corresponding arene precursors. Thus, for 
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example, accessing 23 by biotransformation of biaryl 
carboxylic acid 28 would not be expected to succeed as the 
steric bulk of the tolyl substituent would likely preclude 
docking of 28 in the R. eutrophus B9 BZDO active site. 
Compound 23 is nevertheless accessible, by means of the 5 
indirect route described in this work (Scheme 10). 
 
Scheme 10 
Current efforts in our laboratory are focused on optimising the 
production process for 9 and incorporating this versatile 10 
chiron in the synthesis of more complex targets, including 
appropriate natural products. The results of these endeavours 
will be reported subsequently.  
Experimental 
General 15 
Reactions which required the use of anhydrous, inert 
atmosphere techniques were carried out under an atmosphere 
of nitrogen. Nonacarbonyldiiron was dispensed in a glovebox. 
Solvents were dried and degassed by passing through 
anhydrous alumina columns using an Innovative Technology 20 
Inc. PS-400-7 solvent purification system. Petrol refers to 
petroleum ether, bp 40-60 °C. TLCs were performed using 
aluminium-backed plates precoated with Alugram®SIL G/UV 
and visualized by UV light (254 nm) and/or KMnO4 followed 
by gentle warming. Flash column chromatography was carried 25 
out using Davisil LC 60Å silica gel (35-70 micron) purchased 
from Fisher Scientifics. IR spectra were recorded on Perkin-
Elmer 1600 FT IR spectrometer with absorbances quoted as ν 
in cm-1. NMR spectra were run in CDCl3 (unless otherwise 
specified) on Brüker Avance 250, 300. 400 or 500 MHz 30 
instruments at 298 K. Mass spectra were recorded with a 
micrOTOF electrospray time-of-flight (ESI-TOF) mass 
spectrometer (Brüker Daltonik).  
 
Biotransformation of meta-bromobenzoic acid 35 
This was performed in accordance with a literature 
procedure,8 substituting meta-bromobenzoate for benzoate in 
the biotransformation step. A sterile pipette tip was streaked 
across the surface of a frozen glycerol stock solution of R. 
eutrophus B9 cells to produce small shards (approx. 10 mg). 40 
The frozen shards were added to a sterile 250 mL Erlenmeyer 
flask containing 100 mL of Hutner’s mineral base medium8,33 
and aqueous sodium succinate solution (500 μL of a 1.5 M 
solution). The flask was shaken at 250 rpm for 48 h at 30 °C. 
The culture was then transferred to a 20 L plastic carboy and 45 
additional medium was added to give a total volume of 15 L. 
Air was continuously sparged through the culture. Sodium 
succinate solution (50 mL) was added and the culture was 
incubated for 48 h. The temperature was maintained at 30 °C 
by means of immersed Nalgene® 380 food grade tubing, 50 
through which was passed heated water. Subsequently, 
sodium benzoate solution (5 mL of a 1.0 M solution) was 
added to initiate BZDO expression. After 3 h, sodium meta-
bromobenzoate (50 mL of a 1.0 M solution) and sodium 
succinate (25 mL of a 1.5 M solution) were added. Over the 55 
next 48 h, sodium meta-bromobenzoate solution (1.0 M) and 
sodium succinate solution (1.5 M) were added portionwise. In 
total 60.3g (270 mmol) sodium meta-bromobenzoate and 
48.6g (300 mmol) sodium succinate were introduced. The 
culture was incubated for a further 72 h, then the fermentation 60 
broth was centrifuged at 6000 rpm for 25 min and the 
supernatant liquid decanted. The supernatant was concentrated 
under reduced pressure (rotary evaporator bath temperature 
<40 °C) to a total volume of 1.5 L. The concentrated 
supernatant was then carefully acidified to pH 3.0 with 65 
concentrated hydrochloric acid. The acidified solution was 
then extracted with ethyl acetate (20 × 1 L). After each two 
extractions, the aqueous phase was re-acidified to pH 3.0. 
Each organic extract was dried over MgSO4 and filtered. 
Combined filtrates were concentrated under reduced pressure 70 
to give 51.4 g of crude material, of which unreacted meta-
bromobenzoic acid was the major constituent. This material 
was repeatedly triturated with copious quantities of 
dichloromethane, resulting in dissolution of most of the 
material. (Toluene was also determined to be a suitable 75 
triturant.) After 7 such triturations and drying under vacuum, 
the residual solid material was shown by NMR to be pure 
(1S,6S)-5-bromo-1,6-dihydroxycyclohexa-2,4-dienecarboxylic 
acid 9, a brown powder; 979 mg (4.17 mmol), 1.5%, 65 mg 
dm-3. [α]D
25 -0.16º (c 0.1, CHCl3); δH (300 MHz, CD3OD)
15c 80 
6.30 (1H, dd, J = 6.0, 1.0 Hz CBr=CH), 5.89 (1H, dd, J = 9.5, 
6.0 Hz, CBr=CH-CH), 5.75 (1H, d, J = 9.5 Hz, 
CBr=CH-CH=CH), 4.69 (1H, d, J = 1.0 Hz, HO-CH); δc (75 
MHz, CD3OD) 177.3 (C=O), 130.6 (CBr), 128.5 
(CBr=CH-CH=CH), 127.0 (CBr=CH-CH), 126.7 (CBr=CH), 85 
77.6 (C-COOH), 74.6 (HO-CH); vmax (film) 3220, 1698, 1417, 
1358, 1229, 1091, 1028, 992, 671 cm-1; HRMS (ESI–) m/z 
calcd for (C7H8BrO4–CO2–H2O–H)
–, 170.9446, 172.9425; 
found 170.9446, 172.9422. 
 90 
(1S,6S)-Methyl 5-bromo-1,6-dihydroxycyclohexa-2,4-diene-
carboxylate (11) 
To a stirred solution of 9 (61 mg, 0.260 mmol, 1 equiv) in 
MeOH / benzene (1:1, 32 mL) at room temperature was added 
dropwise (trimethylsilyl)diazomethane (1.5 mL, 2.0 M in 95 
hexanes) until the yellow colour persisted and effervescence 
ceased. The solution was stirred for 2 h then concentrated 
under reduced pressure to give crude (1S,6S)-methyl 5-bromo-
1,6 dihydroxycyclohexa-2,4-diene carboxylate 11 (61 mg, 94 
%) as a brown oil, sufficiently pure to be used without further 100 
purification: Rf 0.73 (50% EtOAc–petrol); [α]D
25 -40º (c 
0.175, CH2Cl2); δH (250 MHz) 6.38 (1H, ddd, J = 6.0, 2.5, 0.5 
Hz, CBr=CH), 5.99 (1H, dd, J = 9.5, 6.0 Hz CBr=CH-CH), 
5.76 (1H, d, J = 9.5 Hz, CBr=CH-CH=CH), 4.79 (1H, br s, 
C(OH)H), 3.89 (3H, s, CH3); δc (75 MHz, CD3OD) 175.5 105 
(C=O),  130.3 (CBr), 127.9, 127.3, 126.8, 78.0 (C-COOMe), 
74.6 (C(OH)H), 53.9 (O-CH3); vmax (film) 3451, 2953, 1734, 
1643, 1572, 1255, 1105, 1034, 940, 809, 695 cm-1; HRMS 
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(ESI+) m/z calcd for (C8H9BrO4+Na)
+, 270.9582, 272.9561; 
found 270.9576, 272.9559. 
 
(3aS,7aS)-Methyl 7-bromo-2,2-dimethyl-3a,7a-dihydrobenzo-
[d][1,3]dioxole-3a-carboxylate (12) 5 
To diol 11 (84 mg, 0.337 mmol, 1 equiv) and para-
toluenesulfonic acid (2.0 mg, 0.01 mmol, 0.03 equiv) in 
acetone (30 mL) was added 2,2-dimethoxypropane  (600 μL, 
4.88 mmol, 14.5 equiv). The reaction mixture was stirred at 
room temperature for 48 h, transferred to a separating funnel, 10 
washed with saturated NaCl(aq) then extracted with EtOAc. 
The organic phase was dried over MgSO4 and filtered. The 
filtrate was concentrated under reduced pressure to give 
(3aS,7aS)-methyl 7-bromo-2,2-dimethyl-3a,7a-dihydrobenzo-
[d][1,3]dioxole-3a-carboxylate 12 (68 mg, 70%) a brown oil, 15 
sufficiently pure to be used without further purification: R f 
0.82 (25% EtOAc–petrol); [α]D
25 -192º (c 0.65, CH2Cl2); δH 
(250 MHz) 6.45 (1H, d, J = 6.0 Hz, CBr=CH), 5.97 (1H, dd, J 
= 9.0, 6.0 Hz, CBr=CH-CH), 5.90 (1H, d, J = 9.0 Hz, 
CBr=CH-CH=CH), 5.08 (1H, s, CH-O-), 3.81 (3H, s, O-CH3), 20 
1.47 (3H, s, C-CH3), 1.43 (3H, s, C-CH3); δc (75 MHz) 171.3 
(C=O), 125.9 (CBr), 124.2, 124.1, 123.3, 108.5 (-O-C-O-), 
81.8 (C-C=O), 78.5 (CH-O), 53.2 (-OCH3), 26.9 (-C-CH3), 
25.5 (-C-CH3); vmax (film) 2971, 1775, 1706, 1602, 1358, 
1240, 1211, 1159, 1009, 957, 758, 723, 687 cm-1; HRMS 25 
(ESI+) m/z calcd for (C11H13BrO4+Na)
+, 310.9895, 312.9874; 
found 310.9886, 312.9873. 
 
(3aS,4R,10R,10aS)-Methyl 10-bromo-2,2-dimethyl-6,8-dioxo-
7-phenyl-4,6,7,8,10,10a-hexahydro-3aH-4,10-etheno[1,3]-30 
dioxolo[4,5-d][1,2,4]triazolo[1,2-a]pyridazine-3a-carboxylate 
13 
To a solution of diene 12 (49 mg, 0.17 mmol, 1 equiv) in 
acetone (4.0 mL) at room temperature was added in a 
dropwise fashion a solution of 4-phenyl-1,2,4-triazoline-3,5-35 
dione in acetone, until a faint red colour of the dione 
persisted. After 1 h, the reaction mixture was concentrated 
under reduced pressure to give (3aS,4R,10R,10aS)-methyl 10-
bromo-2,2-dimethyl-6,8-dioxo-7-phenyl-4,6,7,8,10,10a-
hexahydro-3aH-4,10-etheno[1,3]dioxolo[4,5-d][1,2,4]-40 
triazolo[1,2-a]pyridazine-3a-carboxylate 13 (86 mg, 93% 
yield) as a white crystalline solid: m.p. 172-174 °C 
(EtOAc:Petrol); Rf 0.54 (50% EtOAc–petrol); [α]D
25 -11.5º (c 
0.78, CH2Cl2); δH (300 MHz) 7.44-7.37 (5H, m, Ar-H), 6.62 
(1H, dt, J = 10.0, 1.5 Hz, CBr-CH=CH), 6.37 (1H, dd, J = 45 
10.0, 7.0 Hz, CBr-CH=CH), 5.39 (1H, dd, J = 7.0, 1.5 Hz, 
N-CH-C-COO-), 5.33 (1H, d, J = 1.5 Hz, CBr-CH-O), 3.93 
(3H, s, -OCH3), 1.42 (3H, s, C-CH3), 1.36 (3H, s, C-CH3); δc 
(75 MHz) 169.7 (O-C=O), 154.3 (N-C=O), 154.0 (N-C=O), 
135.4, 130.7, 129.2, 128.8, 127.6, 125.8, 114.3 (-O-C-O-), 50 
84.2, 82.9, 67.7, 53.9, 53.8, 26.2, 26.1; vmax (film) 2993, 1786, 
1721, 1559, 1501, 1457, 1400, 1260, 1214, 1149, 1088, 974, 
880, 754  cm-1; HRMS (ESI+) m/z calcd for 
(C19H18BrN3O6+H)
+, 464.0457, 466.0437; found 464.0449, 
466.0429.  55 
 
(3aS,4R,5R,7aS)-Methyl 7-bromo-4,5-dihydroxy-2,2-
dimethyl-3a,4,5,7a-tetrahydrobenzo[d][1,3]dioxole-3a-
carboxylate (14) 
To a solution of 11 (14.0 mg, 0.048 mmol, 1 equiv) and NMO 60 
(6.6 mg, 0.048 mmol, 1 equiv) in acetone/H2O 4:1 (3 mL) was 
added OsO4 (10 μL, 2.5 wt% in tBuOH, 2 mol%). The 
reaction mixture was stirred at room temperature for 24 h, 
then diluted with Na2S2O3(aq) and extracted with EtOAc. The 
organic extracts were dried over MgSO4 and filtered. The 65 
filtrate was concentrated under reduced pressure and purified 
by column chromatography (40% EtOAc–petrol) to give 
(3aS,4R,5R,7aS)-methyl 7-bromo-4,5-dihydroxy-2,2-dimethyl-
3a,4,5,7a-tetrahydrobenzo[d][1,3]dioxole-3a-carboxylate 14 
(11 mg, 80%) as a colourless oil: Rf 0.32 (40% EtOAc–70 
petrol); [α]D
25 -5.5º (c 0.55, CH2Cl2); δH (500 MHz) 6.23 (1H, 
d, J = 2.5 Hz, CBr=CH), 5.08 (1H, d, J = 0.5 Hz, CBr-CH-O), 
4.42 (1H, br s, CHCH(OH)CH(OH)), 4.32 (1H, br s, 
CHCH(OH)CH(OH)), 3.87 (3H, s, -OCH3), 2.80 (1H, br 
s, -OH), 2.76 (1H, br s, -OH), 1.46 (3H, s, C-CH3) 1.41 (3H, 75 
s, C-CH3); δc (75 MHz) 170.8 (C=O), 130.9 (CBr=CH), 121.2 
(CBr), 111.3 (-O-C-O-), 83.5 (C-COOCH3), 77.1 
(CBr-CH-O-C), 69.9 (C-OH), 66.2 (C-OH), 52.2 (O-CH3), 
26.4 (C-CH3), 25.8 (C-CH3); vmax (film) 3405, 1734, 1647, 
1373, 1236, 1098, 1062, 620 cm-1; HRMS (ESI+) m/z calcd 80 
for (C11H15BrO5+Na)
+, 344.9950, 346.9929; found 344.9948, 
346.9935. 
 
((3aR,7aS)-7-Bromo-2,2-dimethyl-3a,7a-dihydrobenzo-
[d][1,3]dioxol-3a-yl)methanol 17 85 
To ester 12 (68.9 mg, 0.235 mmol, 1 equiv) was added lithium 
aluminium hydride (9.0 mg, 0.237 mmol, 1 equiv) as a 
solution in diethyl ether (25 mL). The reaction mixture was 
stirred at room temperature for 1 h, then cooled to 0 °C. 
Excess EtOAc was added dropwise by syringe to quench 90 
unreacted reductant, then the reaction mixture was cautiously 
added to a saturated aqueous solution of sodium potassium 
tartrate (Rochelle’s salt). The reaction mixture was stirred 
vigorously for 1 h, then the phases were separated. The 
organic phase was dried over MgSO4 then filtered. The filtrate 95 
was concentrated under reduced pressure and purified by 
chromatography (30% EtOAc–petrol) to afford  ((3aR,7aS)-7-
bromo-2,2-dimethyl-3a,7a-dihydrobenzo[d][1,3]dioxol-3a-
yl)methanol (17) (7.0 mg 11%) as a colourless oil. 
Debrominated product ((3aR,7aS)-2,2-dimethyl-3a,7a-100 
dihydrobenzo[d][1,3]dioxol-3a-yl)methanol (16) was also 
isolated. Alcohol 17: Rf 0.45; (30% EtOAc–petrol); 
[α]D
25 -10º (c 0.2, CH2Cl2); δH (300 MHz) 6.42 (1H, dd, J = 
6.0, 0.5 Hz, BrC=CH), 5.90 (1H, dd, J = 9.5, 6.0 Hz, 
BrC=CH-CH), 5.78 (1H, dd, J = 9.5, 0.5 Hz, 105 
BrC=CH-CH=CH), 4.91 (1H, s, CH-O-), 3.61 (1H, d, J = 11.5 
Hz, -CHH-OH), 3.44 (1H, dd, J = 11.5, 7.0 Hz, -CHH-OH), 
1.85 (1H, br s, -OH), 1.49 (3H, s, CH3), 1.39 (3H, s, CH3); δc 
(75 MHz) 127.9, 126.4, 123.4, 123.3, 107.9 (-O-C-O-), 82.9 
(C-CH2OH), 77.7 (CH-O-C), 64.7 (-CH2OH), 27.0 (CH3), 110 
26.9 (CH3); vmax (film) 3413, 2918, 2956, 2852, 1465, 1383, 
1222, 1943, 750 cm-1; HRMS (ESI+) m/z calcd for 
(C10H11BrO3+Na)
+, 282.9946: 284.9925; found 282.9932, 
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(4S)-Tricarbonyl(η4-(3aS,7aS)-methyl 7-bromo-2,2-dimethyl-
3a,7a-dihydrobenzo[d][1,3]dioxole-3a-carboxylate)iron(0) 
(21) and (4R)-Tricarbonyl(η4-(3aS,7aS)-methyl 7-bromo-2,2-5 
dimethyl-3a,7a-dihydrobenzo[d][1,3]dioxole-3a-carboxylate)-
iron(0) (22) 
To a flask containing 12 (185 mg, 0.59 mmol, 1 equiv) in a 
glovebox was added nonacarbonyldiiron (440 mg, 1.21 mmol, 
2 equiv). THF (40 mL) was added and the reaction mixture 10 
was stirred at room temperature for 7 d. The reaction mixture 
was then concentrated under reduced pressure (Care! Toxic 
pentacarbonyliron distilled over at this point) and purified by 
column chromatography (10% EtOAc–petrol) to give (4S)-
tricarbonyl(η4-(3aS,7aS)-methyl 7-bromo-2,2-dimethyl-3a,7a-15 
dihydrobenzo[d][1,3]dioxole-3a-carboxylate)iron(0) 21 as fine 
brown needles (43 mg, 17%) and (4R)-tricarbonyl(η4-
(3aS,7aS)-methyl 7-bromo-2,2-dimethyl-3a,7a-dihydrobenzo-
[d][1,3]dioxole-3a-carboxylate)iron(0) 22 as a brown oil (36 
mg, 14%). Unreacted 12 (100 mg, 60%) was also isolated. 20 
Complex 21: m.p. 95-97 °C (EtOAc:petrol); Rf 0.32 (10% 
EtOAc–petrol); [α]D
25 -10º (c 0.2, CH2Cl2); δH (300 MHz) 
5.95 (1H, dt, J = 4.5, 1.5 Hz, CBr=CH), 5.47 (1H, dd, J = 6.5, 
4.5 Hz, CBr=CH-CH=), 5.36 (1H, d, J = 1.5 Hz, CH-O-), 3.88 
(3H, s, O-CH3), 3.06 (1H, dd, J = 6.5, 1.0 Hz, 25 
CBr=CH-CH=CH), 1.45 (3H, s, C-CH3), 1.23 (3H, s, C-CH3); 
δc (75 MHz) 171.3 (-COOMe), 117.8 (-O-C-O-), 89.9 
(CBr=CH), 87.0 (C-COOMe), 86.7 (CH-O-), 83.6 (CBr=CH-
CH=), 70.2 (CBr), 54.0 (CBr=CH-CH=CH), 53.3 (O-CH3), 
28.1 (C-CH3), 27.3 (C-CH3); vmax (film) 2981, 2068, 2003, 30 
1730, 1437, 1375, 1261, 1214, 1162, 1062, 1027, 978, 865, 
752, 687, 636 cm-1; HRMS (ESI+) m/z calcd for 
(C14H13BrFeO7+Na)
+, 450.9092, 452.9071; found 450.9106, 
452.9164.  Complex 22: Rf 0.26 (10% EtOAc–petrol); 
[α]D
25 -90º (c 0.6, CH2Cl2); δH (500 MHz) 5.76 (1H, d, J = 3.5 35 
Hz, CBr=CH), 5.15 (1H, dd, J = 6.0, 4.5 Hz, CBr=CH-CH=), 
4.60 (1H, s, CH-O-), 3.75 (3H, s, O-CH3), 2.97 (1H, d, J = 6.5 
Hz, CBr=CH-CH=CH), 1.71 (3H, s, C-CH3), 1.20 (3H, s, 
C-CH3); δc (75 MHz) 207.1 (Fe C=O), 173.3 (-COOMe), 
109.7 (-O-C-O-), 89.3 (CBr=CH), 85.4 (C-COOMe), 84.8 40 
(CH-O-), 80.5 (CBr=CH-CH=), 73.6 (CBr), 61.2 
(CBr=CH-CH=CH), 53.1 (O-CH3), 25.0 (C-CH3), 24.2 
(C-CH3); vmax (film) 2980, 2061, 1995, 1729, 1460, 1380, 
1252, 1207, 1168, 1070, 1030 cm-1; HRMS (ESI+) m/z calcd 
for (C14H13BrFeO7+Na)
+, 450.9092, 452.9071; found 45 
450.9091, 452.9073. 
 
(3aS,7aR)-Methyl 2,2-dimethyl-7-(para-tolyl)-3a,7a-dihydro-
benzo[d][1,3]dioxole-3a-carboxylate 24 
Bromodiene 12 (25.0 mg, 0.096 mmol, 1 equiv), 50 
tetrakis(triphenylphosphine)palladium (2.0 mg, 0.002 mmol, 2 
mol %), para-tolylboronic acid (105 mg, 0.78 mmol, 8 equiv) 
and potassium carbonate (238 mg, 1.73 mmol, 18 equiv) were 
dissolved in DMF/H2O 5:1 (30 mL) and stirred at room 
temperature for 72 h. The reaction mixture was diluted with 55 
EtOAc and washed with water. The organic layer was devoid 
of product; thus, the aqueous layer was concentrated under 
reduced pressure to afford crude free acid cross-coupling 
product 23. The crude acid 23 was then dissolved in 
MeOH/benzene 1:1 (35 mL) and (trimethylsilyl)diazomethane 60 
(1.5 mL, 2.0 M in hexanes) was added dropwise with stirring 
until the yellow colour persisted and effervescence ceased. 
The solution was stirred for 2 h then concentrated under 
reduced pressure. Purification by column chromatography 
(10% EtOAc–petrol) gave (3aS,7aR)-methyl 2,2-dimethyl-7-65 
(para-tolyl)-3a,7a-dihydrobenzo[d][1,3]dioxole-3a-
carboxylate (24) (8 mg, 30 % over two steps) as a colourless 
oil: Rf 0.36 (5% EtOAc–petrol); [α]D
25 -156º (c 0.3, CH2Cl2); 
δH (250 MHz) 7.50 (2H, d, J = 8.0 Hz, Ar-H), 7.18 (2H, d, J = 
8.0 Hz, Ar-H) 6.48 (1H, d, J = 6.0 Hz, Ar-C=CH), 6.23 (1H, 70 
dd, J = 9.5, 6.0 Hz, Ar-C=CH-CH), 5.83 (1H, d, J = 9.5 Hz, 
Ar-C=CH-CH=CH), 5.26 (1H, s, CH-O-C), 3.77 (3H, s, 
O-CH3), 2.36 (3H, s, Ar-CH3), 1.53 (3H, s, C-CH3), 1.42 (3H, 
s, C-CH3); δc (75 MHz) 171.8 (C=O), 138.2 (4°), 135.3 (4°), 
134.6 (4°), 129.4 (3° Ar), 125.8 (3° Ar), 124.8 75 
(Ar-C=CH-CH), 124.5 (Ar-C=CH-CH=CH), 119.7 
(Ar-C=CH), 107.6 (-O-C-O-), 81.2 (C-COOMe), 74.6 
(CH-O-), 53.1 (O-CH3), 27.1 (C-CH3), 25.4 (C-CH3), 21.4 
(Ar-CH3); vmax (film) 2973, 2937, 2888, 1741, 1469, 1381, 
1308, 1163, 1131, 1105, 951, 821 cm-1; HRMS (ESI+) m/z 80 
calcd for (C18H20O4+Na)
+, 323.1259; found 323.1258.  
 
(3aS,7aR)-Methyl 2,2-dimethyl-7-((triisopropylsilyl)ethynyl)-
3a,7a-dihydrobenzo[d][1,3]dioxole-3a-carboxylate 25 
To a solution of bromodiene 12 (81 mg, 0.28 mmol, 1 equiv), 85 
tetrakis(triphenylphosphine)palladium (16 mg, 0.014 mmol, 5 
mol %), copper(I) iodide (3.7 mg, 0.0196 mmol, 7 mol %) 
dissolved in THF (20 mL), was added by syringe n-
butylamine (110 μL, 1.12 mmol, 4 equiv) and (triiso-
propyl)acetylene (100 μL, 0.45 mmol, 1.6 equiv). The 90 
reaction mixture was stirred at room temperature for 24 h, 
then diluted with EtOAc and washed with NH4Cl(aq) and 
NaCl(aq). The organic phase was dried over MgSO4 and 
filtered. The filtrate was concentrated under reduced pressure 
and purified by column chromatography (10% EtOAc–petrol) 95 
to give (3aS,7aR)-methyl 2,2-dimethyl-7-((triisopropyl-
silyl)ethynyl)-3a,7a-dihydrobenzo[d][1,3]dioxole-3a-
carboxylate (25) (108 mg, 98%) as a yellow oil: Rf 0.45 (10% 
EtOAc–petrol); [α]D
25 -176º (c 0.89, CH2Cl2); δH (250 MHz) 
6.37 (1H, d, J = 6.0 Hz, SiC≡C-C=CH), 6.12 (1H, dd, J = 9.5, 100 
6.0 Hz, SiC≡C-C=CH-CH), 5.85 (1H, dd, J = 9.5, 0.5 Hz, 
SiC≡C-C=CH-CH=CH), 4.91 (1H, d, J = 0.5 Hz, CH-O-), 
3.78 (3H, s, O-CH3), 1.45 (3H, s, C-CH3), 1.39 (3H, s, 
C-CH3), 1.08 (21H, br s, Si-CH and Si-CH-CH3); δc (75 MHz) 
171.7 (C=O), 129.0 (alkene C), 125.0 (alkene C), 124.4 105 
(alkene C), 120.7 (alkene C), 108.2 (-O-C-O-), 105.5 (alkyne 
C), 96.7 (alkyne C), 80.0 (C-COOMe), 75.6 (CH-O-), 53.0 
(O-CH3), 26.9 (C-CH3), 25.6 (C-CH3), 18.6 (Si-C-CH3), 11.3 
(Si-C-CH3); vmax (film) 2943, 2865, 2158, 2032, 1741, 1462, 
1381, 1243, 1039, 883, 677 cm-1; HRMS (ESI+) m/z calcd for 110 
(C22H34O4Si+Na)
+, 413.2124; found 413.2127. 
 
(3aS,7aR)-Methyl 7-ethynyl-2,2-dimethyl-3a,7a-dihydro-
benzo[d][1,3]dioxole-3a-carboxylate 26 
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To a stirred solution of silylacetylene 25 (9.6 mg, 0.03 mmol, 
1 equiv) in THF (30 mL) at room temperature was added 
tetra-n-butylammonium fluoride (1.0 M solution in THF, 0.05 
mL, 0.05 mmol, 1.1 equiv). The reaction mixture was stirred 
for 24 h, then diluted with EtOAc and washed with NaCl (aq). 5 
The organic layer was dried over MgSO4 and filtered. The 
filtrate was concentrated under reduced pressure and purified 
by column chromatography (15% EtOAc–petrol) to give 
(3aS,7aR)-methyl 7-ethynyl-2,2-dimethyl-3a,7a-dihydro-
benzo[d][1,3]dioxole-3a-carboxylate (26) (4.4 mg, 0.015 10 
mmol, 76 %) as a pale white gum: Rf 0.24 (15% EtOAc–
petrol); [α]D
25 -184º (c 0.32, CH2Cl2); δH (400 MHz) 6.46 (1H, 
d, J = 6.0 Hz, HC≡C-C=CH), 6.14 (1H, dd, J = 9.5, 6.0 Hz, 
HC≡C-C=CH-CH), 5.90 (1H, d, J = 9.5 Hz, 
HC≡C-C=CH-CH=CH), 4.92 (1H, s, CH-O-), 3.80 (3H, s, 15 
O-CH3), 3.23 (1H, s, C≡CH), 1.48 (3H, s, C-CH3), 1.43 (3H, 
s, C-CH3); δc (75 MHz) 171.5 (C=O), 130.6 (HC≡C-C=CH), 
126.1 (HC≡C-C=CH-CH=CH), 123.8 (HC≡C-C=CH-CH), 
118.8 (HC≡C-C=), 108.1 (-O-C-O-), 82.6 (HC≡C), 81.8 
(HC≡C), 80.1 (C-COOMe), 75.0 (CH-O), 53.3 (O-CH3), 27.0 20 
(C-CH3), 25.4 (C-CH3); vmax (film) 2981, 2889, 1737, 1462, 
1382, 1251, 1152, 954, 807 cm-1; HRMS (ESI+) m/z calcd for 
(C13H14O4+Na)
+, 257.0784; found 257.0751. 
 
(3aS,7aR)-Methyl 7-(1-benzyl-1H-1,2,3-triazol-4-yl)-2,2-25 
dimethyl-3a,7a-dihydrobenzo[d][1,3]dioxole-3a-carboxylate 
27 
To a stirred solution of terminal alkyne 26 (13.0 mg, 0.05 
mmol, 1 equiv) in EtOH/H2O 5:1 (25 mL) were added benzyl 
azide (7.9 mg, 0.06 mmol, 1.2 equiv), CuSO4 (1.1 mg, 1 mol 30 
%) and ascorbic acid (5.9 mg, 10 mol%). The solution was 
stirred at room temperature for 48 h, then diluted with NaCl (aq) 
and extracted with EtOAc. The organic layer was dried over 
MgSO4 and filtered. The filtrate was concentrated under 
reduced pressure and purified by column chromatography 35 
(10% to 50% EtOAc–petrol) to give unreacted 26 (7.8 mg, 
66%) and (3aS,7aR)-methyl 7-(1-benzyl-1H-1,2,3-triazol-4-
yl)-2,2-dimethyl-3a,7a-dihydrobenzo[d][1,3]dioxole-3a-
carboxylate (27) (6.3 mg, 34%) as a pale brown oil: Rf 0.48 
(50% EtOAc–petrol); [α]D
25 -40º (c 0.18, CH2Cl2); δH (300 40 
MHz) 7.62 (1H, s, HetAr-H), 7.37-7.29 (5H, m, Ph-H) 6.94 
(1H, d, J = 6.0 Hz, HetAr-C=CH-), 6.28 (1H, dd, J = 9.0, 6.0 
Hz, HetAr-C=CH-CH=), 5.92 (1H, d, J = 9.0 Hz, 
HetAr-C=CH-CH=CH), 5.61 (1H, d, J = 15.0 Hz, Ph-CHH-), 
5.49 (1H, d, J = 15.0 Hz, Ph-CHH-) 5.27 (1H, s, CH-O-), 3.78 45 
(3H, s, O-CH3), 1.48 (3H, s, C-CH3), 1.34 (3H, s, C-CH3); δc 
(75 MHz) 172.0 (C=O), 134.8, 129.3, 128.8, 128.1, 127.8, 
126.1, 124.9, 124.5, 121.0 (3º HetAr), 119.7 (HetAr-C=CH-), 
108.7 (-O-C-O-), 80.6 (C-COOMe), 74.2 (CH-O-), 54.3 
(Ph-CH2-), 53.2 (O-CH3), 27.1 (C-CH3), 25.8 (C-CH3); vmax 50 
(film) 2995, 2917, 1857, 1739, 1496, 1457, 1258, 1066, 887, 
799, 727 cm-1; HRMS (ESI+) m/z calcd for 
(C20H21N3O4+Na)
+, 390.1429; found 390.1440.   
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